Biogen (BIIB) PT Raised to $321 at Morgan Stanley
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $210.65 --0%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 7 | New: 6
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 7 | New: 6
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison raised the price target on Biogen (NASDAQ: BIIB) to $321.00 (from $285.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Jefferson Capital (JCAP) PT Raised to $24 at Raymond James
- Workday (WDAY) PT Raised to $220 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
